INTRODUCTION
============

The early growth response (Egr) family of zinc finger transcription factors regulates critical genetic programs in cellular growth, differentiation, and function \[[@b1-ajas-30-6-781],[@b2-ajas-30-6-781]\]. There are four Egr members, Egr1, Egr2, Egr3, and Egr4, and each member has specific and overlapping functions in a given physiological setting. Some Egr factors have shown to be involved in reproductive function. Egr1 regulates expression of the luteinizing hormone beta subunit, and *Egr1* deficient mice suffer from female infertility resulting from hormone insufficiency \[[@b3-ajas-30-6-781]\]. Egr1 is induced by estrogen in the mouse uterus and expressed in stromal cells surrounding implanting blastocysts, suggesting a role for Egr1 in uterine biology \[[@b4-ajas-30-6-781]\]. Egr3 is implicated in neurodevelopment, learning and memory, immune response, and fibrogenic response \[[@b5-ajas-30-6-781]--[@b8-ajas-30-6-781]\], and this list shows functional diversity of this factor. As for *Egr3* deficient mice, neurodevelopmental phenotypes are well described \[[@b5-ajas-30-6-781]\]. Whether Egr3 deficiency leads to other tissue-specific functions is just beginning to unravel with the availability of the *Egr3* floxed mice \[[@b9-ajas-30-6-781]\]. In reproduction, expression of Egr3 in mouse oocytes and spermatocytes was reported by us \[[@b2-ajas-30-6-781]\]. In bovine granulosa cells, the administration of mycotoxin was shown to induce Egr3 expression \[[@b10-ajas-30-6-781]\]. Expression of Egr3 and Egr4 in the pig ovary is also recently reported \[[@b11-ajas-30-6-781]\]. In male mice, Egr4 exhibits a dynamic pattern of localization in germ cells and gonadal somatic cells depending on the stage of sexual maturity \[[@b12-ajas-30-6-781]\].

Previously, we showed that the immunoreactive Egr3 colocalizes with meiotic spindle and accumulates near cytosolic microtubule organizing centers (MTOCs) in oocytes during meiotic maturation. As a transcription factor, Egr3 was expected to localize to nucleus in cells and tissues, but localization of the immunoreactive Egr3 was noted in the cytoplasmic structures in mouse oocytes, early preimplantation embryos, and spermatocytes \[[@b2-ajas-30-6-781]\]. Several transcriptional regulators including Egr1 have been reported to exhibit similar localization on microtubule-associated structures \[[@b13-ajas-30-6-781]--[@b15-ajas-30-6-781]\].

In this study, we elaborate further on the expression of Egr3 in gonads and its role in oocyte maturation. Whereas several pieces of information indicate involvement of Egr factors in female reproduction, it is not clear if Egr3 is required for oocyte maturation in mice. Thus, we herein investigated if functional blockade of Egr3 hinders meiotic maturation of oocytes by microinjecting dominant-negative Egr3 complementary RNA (cRNA) and small interfering RNA (siRNA) specific to *Egr3*. The results show that Egr3 is dispensable for meiotic maturation in mouse oocytes and that some of the commercially available anti-Egr3 antibodies may not faithfully represent endogenous and exogenous Egr3 proteins in oocytes.

MATERIALS AND METHODS
=====================

Mice
----

All mice were maintained in accordance with the policies of the Konkuk University Institutional Animal Care and Use Committee (IACUC). This study was approved by the Konkuk University IACUC (approval number KU15109). Mice were sacrificed after administration of avertin to minimize suffering. Four-week-old virgin ICR or BDF female mice were purchased from Orient-Bio (Seongnam, Korea).

Collection and culture of oocytes
---------------------------------

Four-to-five-week-old virgin CrljOri:CD-1 (ICR) female mice were intraperitoneally injected with 7.5 IU of pregnant mare's serum gonadotropin (Sigma-Aldrich, St. Louis, MO, USA) to induce folliculogenesis. Fully grown follicles were punctured 48 h later and cumulus-oocyte complexes were collected. The cumulus cells were then removed by using 300 μg/mL hyaluronidase (Sigma-Aldrich, USA) and germinal vesicle (GV) stage oocytes were retrieved in Quinn's Advantage Medium with HEPES (Sage BioPharma Inc., Bedminster, NJ, USA) containing 10% substitute protein serum and 200 μM 3-isobutyl-1-methylxanthine (IBMX) (I5879; Sigma-Aldrich, USA). Cumulus cells were gently removed from the cumulus-oocyte complexes using a Pasteur glass pipette. The oocytes were incubated in microdrops of M16 medium (M7292; Sigma-Aldrich, USA) containing 200 μM IBMX covered with mineral oil (Sage, USA) at 37°C under 5% CO~2~ in atmosphere until microinjection was conducted. After microinjection, these oocytes were placed in drops of M16 medium with 200 μM IBMX for 8 h. For oocyte maturation, these oocytes were placed in IBMX-free M16 medium for 20 h. Rates of GV breakdown (GVBD) and polar body extrusion were monitored.

Reverse transcription-polymerase chain reaction
-----------------------------------------------

Reverse transcription-polymerase chain reaction (RT-PCR) was conducted as described previously \[[@b2-ajas-30-6-781]\]. Gonads were individually collected from 1, 2, 3, and 4 week-old female and male ICR mice. Each sample was subjected to RNA preparation by using TRI Reagent (Life Technologies, Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Isolated RNA (2 μg) was subjected to reverse transcription (RT) using M-MLV reverse transcriptase (Beams Biotechnology, Seongnam, Korea). PCR was carried out using Prime Taq Premix (Genet Bio, Daejeon, Korea). Primer sequence are given in [Table 1](#t1-ajas-30-6-781){ref-type="table"}. PCR reaction was also performed for the mouse ribosomal protein L7 (*Rpl7*), a housekeeping gene. Annealing temperature is 59°C for all reactions. This experiments were repeated 6 times with independent samples.

Plasmid constructs
------------------

Full-length mouse *Egr3* gene (NM_018781.3) was amplified by PCR from the mouse ovary cDNA sample \[[@b2-ajas-30-6-781]\]. To generate the dominant negative form of Egr3 \[[@b16-ajas-30-6-781]\], the truncated form of Egr3 (missing the first 249 amino acids, ΔEgr3) was generated by PCR from the full-length mouse *Egr3* cDNA. Full-length and truncated *Egr3* DNAs were inserted into BglII and AgeI site of pDsRed2-N1 vector (Clontech, Mountain View, CA, USA) and cloned into KpnI and XhoI site of pcDNA3.1/Myc-His vector (Invitrogen, USA). For *in vitro* transcription, full-length and truncated *Egr3* construct containing Xpress tag at the N-terminus and DsRed2 at the C-terminus were amplified by PCR and cloned into BamHI and HindIII site of pRSET-A vector (Invitrogen, USA). The constructs are shown in [Figure 1A, 1B](#f1-ajas-30-6-781){ref-type="fig"}.

*In vitro* transcription and microinjection
-------------------------------------------

For live imaging of Egr3 expression in mouse oocytes, full-length and truncated Egr3 cRNAs were produced by *in vitro* transcription using mMessage mMachine T7 transcription kit (Ambion, Austin, TX, USA). To visualize microtubule in some experiments, β-tubulin-green fluorescent protein (GFP) cRNA was produced from pRN3-β-tubulin-GFP construct (a gift from Marie-Hélène Verlhac, CIRB, Collège de France, Paris, France) using T3 transcription kit. These RNAs were cleaned and concentrated by using RNeasy MinElute Clean up kit (Qiagen, Valencia, CA, USA). These constructs were confirmed by *in vitro* translation by using TNT T7 Coupled Reticulocyte Lysate System kit (Promega, Madison, WI, USA). SMARTpool *Egr3* siRNA (\#M-046392-01-0005) and non-targeting siRNA (\#D-001810-01-05) were purchased from Dharmacon (Lafayette, CO, USA). Knockdown capacity of this siRNA was first confirmed in 293T cells transfected with full-length Egr3 plasmid. *Egr3* siRNA (25 μM) was microinjected into GV oocytes and rates of GVBD and polar body extrusion were monitored.

To visualize Egr3 localization by live imaging, Egr3-DsRed2 or truncated Egr3-DsRed2 cRNA (0.0034 μM) was microinjected into GV oocytes. Injection volume was 5 to 10 pL, which is about 1% to 3% of total oocyte volume. Mouse oocytes were placed in drops of culture media containing 200 μM IBMX for microinjection. Microinjection of cRNA or siRNA was performed using a Nikon (Nikon Corporation, Shinagawa-Ku, Tokyo, Japan) manipulator with picoinjector (Femtojet, Eppendorf, Hamburg, Germany) via pneumatic pressure.

Immunofluorescence staining
---------------------------

The oocytes injected with *Egr3* siRNA or Xpress-ΔEgr3-DsRed2 RNA were fixed in 3.7% formaldehyde in phosphate-buffered saline (PBS) and permeabilized in 0.25% triton X-100 in PBS. They were blocked and incubated with 4 μg/mL antibody or 2 μg/mL antibody of specific primary antibodies. Primary antibodies are the rabbit polyclonal anti-Egr3 antibody (sc-191; Santa Cruz Biotechnology, CA, USA) and the mouse anti-Xpress antibody (P/N 46-0528; Invitrogen, USA). Primary antibodies were probed with chick anti-rabbit IgG-Alexa Fluor 488 antibody and donkey anti-mouse IgG-Alexa Flour 488 antibody (1:250; Invitrogen, USA). DNA was counter-stained with TO-PRO-3-iodide (1:500; Invitrogen, USA). Rabbit IgG was used at the same concentration as a mock control in each experiment. Images were obtained using the Olympus Fluoview FV1000 spectral confocal microscope (Tokyo, Japan) and analyzed using the software Fluoview version 1.5, a platform associated with the confocal microscope.

Protein extraction and western blotting
---------------------------------------

293T cells were co-transfected with pcDNA3.1/Myc-Egr3 plasmid and *Egr3* siRNA. Cells transfected with empty plasmid or non-targeting siRNA served as negative controls. Cell lysates were prepared in RIPA buffer (50 mM Tris \[pH 7.5\], 150 mM NaCl, 1% Nonidet P-40, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1X Protease Inhibitor \[Roche, Indianapolis, IN, USA\]) and centrifuged at 13,000 rpm. The supernatant was subjected to bicinchoninic acid (BCA) assays (Thermo Scientific, Rockford, IL, USA) for quantitation. Fifty micrograms of protein were loaded per lane and separated in 10% SDS-polyacrylamide gel electrophoresis (PAGE) gels. Western blotting was performed as previously described \[[@b2-ajas-30-6-781]\]. Anti-α-tubulin (Sigma-Aldrich, USA) and anti-Egr3 (sc-191; Santa Cruz Biotechnology, USA) antibodies were used at 1:2,000 and 1:500, respectively. Anti-Myc antibody (\#631206; Clontech, USA) was used at 1:2,000. Horseradish peroxidase (HRP) -conjugated goat anti-rabbit and goat anti-mouse antibodies (GeneDEPOT, Barker, TX, USA) were used at 1:10,000. Super Signal West Femto ECL reagent (Thermo Scientific, USA) was used. Chemiluminescence signal was detected by LAS3000 (FUJIFILM, Tokyo, Japan).

RESULTS
=======

Expression of *Egr3* in ovaries and testes in mice
--------------------------------------------------

To examine if *Egr3* is expressed in mouse gonads at different stages of sexual maturation, we collected ovaries and testes from 1, 2, 3, and 4 week-old mice. The location of primers is depicted in [Figure 1A](#f1-ajas-30-6-781){ref-type="fig"}. RT-PCR analysis showed that *Egr3* mRNA is expressed in ovaries and testes in all groups. We also found that an uncharacterized longer transcript of *Egr3* (NM_001289925.1) was present in 3 and 4-week-old gonads ([Figure 2](#f2-ajas-30-6-781){ref-type="fig"}). Whether this form of Egr3 is functional or expressed in other tissues is not known.

Microinjection of full-length and truncated Xpress-Egr3-DsRed2 does not hinder oocyte maturation
------------------------------------------------------------------------------------------------

We previously showed that the immunoreactive Egr3 is specifically localized near MTOCs and on spindle during meiotic maturation of oocytes \[[@b2-ajas-30-6-781]\]. We examined the subcellular localization of Egr3 with live imaging after microinjecting full-length Egr3 cRNA. This construct has an Xpress tag at N-terminus and DsRed2 at C-terminus ([Figure 1B](#f1-ajas-30-6-781){ref-type="fig"}). We also microinjected truncated Egr3 RNA (Xpress-ΔEgr3-DsRed2) lacking the first 249 amino acids, which is known as a dominant-negative form of Egr3 \[[@b16-ajas-30-6-781]\] ([Figure 1B](#f1-ajas-30-6-781){ref-type="fig"}). As shown in [Figure 3](#f3-ajas-30-6-781){ref-type="fig"} by confocal live imaging, products of both Xpress-Egr3-DsRed2 and Xpress-ΔEgr3-DsRed2 cRNAs localize to nucleus and chromosomes during meiotic maturation. We then monitored if microinjection of these Egr3 RNAs affect meiotic maturation rate in oocytes. Microinjection of either construct did not influence the rate of meiotic maturation ([Table 2](#t2-ajas-30-6-781){ref-type="table"}).

Meiotic maturation is not hindered by *Egr3* siRNA in oocytes
-------------------------------------------------------------

We next tested if microinjection of *Egr3* siRNA has any influence on meiotic maturation. The specificity of *Egr3* siRNA was first confirmed by western blotting in 293T cells transfected with Egr3-Myc plasmid ([Figure 4A](#f4-ajas-30-6-781){ref-type="fig"}). However, microinjection of *Egr3* siRNA to GV oocytes did not affect GVBD or polar body formation ([Table 3](#t3-ajas-30-6-781){ref-type="table"}). Spindle forms normally in metaphase I (MI) oocytes injected with *Egr3* siRNA, as evidenced by normal distribution of tubulin-GFP ([Figure 4B](#f4-ajas-30-6-781){ref-type="fig"}).

Egr3 localization: potential artefact in immunolocalization
-----------------------------------------------------------

The observation that the microinjected Xpress-ΔEgr3-DsRed2 constructs are only confined to nuclei and chromosomes contradicts our previous observation that immunoreactive Egr3 localized to MTOCs and microtubules \[[@b2-ajas-30-6-781]\]. Thus, we side-by-side compared localization of Egr3 in microinjected oocytes by confocal live imaging, and anti-Xpress and anti-Egr3 immunofluorescence staining in fixed oocytes. As shown in [Figure 5](#f5-ajas-30-6-781){ref-type="fig"}, DsRed2 signal is clearly confined to chromosomes. Anti-Xpress antibody detected a diffuse pattern of signal on or near metaphase chromosomes. This pattern is less clear than DsRed2 live imaging, but some signal overlaps with DNA. In contrast, anti-Egr3 antibody shows positive signal only on meiotic spindle ([Figure 5](#f5-ajas-30-6-781){ref-type="fig"}). This anti-Egr3 antibody does not detect exogenous Xpress-ΔEgr3-DsRed2, because the signal is negative on chromosomes. This result suggests that spindle-positive signal detected by anti-Egr3 antibody seems to be nonspecific.

DISCUSSION
==========

In this study, we show that mouse gonads express *Egr3* mRNA, both at immature and sexually maturing stages of age. Herein we present experiments to test functionality of Egr3 in mouse oocytes, providing evidence that Egr3 is dispensable for meiotic maturation in mouse oocytes.

In RT-PCR analysis, a bigger, uncharacterized *Egr3* isoform was noted in 3 and 4-week ovaries. This variant, NM_001289925.1, has another exon inserted between two original exons of the mouse *Egr3* gene ([Figure 1A](#f1-ajas-30-6-781){ref-type="fig"}). This form using a downstream start codon is expected to produce a shorter product with distinct N-terminus. Several isoforms of Egr3 have been reported in brain and they seem to have different transcriptional activity \[[@b17-ajas-30-6-781],[@b18-ajas-30-6-781]\]. Interestingly, the appearance of this variant is associated with sexual maturation of the ovary. Whether this particular variant in mouse gonads is expressed in brain or other tissues and functionally active is currently unknown.

Egr3 without the N-terminal half of the protein is known as a dominant-negative form which blocks activity of Egr factors \[[@b16-ajas-30-6-781]\]. Commercially available siRNA specific to *Egr3* efficiently downregulates translation of Egr3 ([Figure 4A](#f4-ajas-30-6-781){ref-type="fig"}). Microinjection of either dominant-negative Egr3 or *Egr3* siRNA did not influence the rates of GVBD and PB extrusion, suggesting that Egr3 is functionally dispensable during oocyte maturation ([Tables 2](#t2-ajas-30-6-781){ref-type="table"}, [3](#t3-ajas-30-6-781){ref-type="table"}). During the course of this study, we noticed that Xpress-Egr3-DsRed2 and Xpress-ΔEgr3-DsRed2 proteins are confined only on nuclei and chromosomes after microinjection when observed by live imaging ([Figure 3](#f3-ajas-30-6-781){ref-type="fig"}). This is in discrepancy with our previous observation that anti-Egr3 antibody produced signal near MTOC and on spindle of maturing oocytes. In our previous study, we had tested five commercially available anti-Egr3 antibodies and two of them had produced the observed pattern of localization in oocytes \[[@b2-ajas-30-6-781]\] ([Figure 5](#f5-ajas-30-6-781){ref-type="fig"}). Both antibodies, detecting C-terminal region of Egr3 protein, detect Egr3 in western blotting and recognize exogenous Egr3 in nuclei of PC12 or MCF7 cells. Interestingly, one of these antibodies also detect immunoreactive Egr3 in growing neurites of PC12 cells (data not shown). Thus, certain anti-Egr3 antibody recognizes microtubule-based subcellular structures both in PC12 and mouse oocytes; neurite and meiotic spindle. The similarity between these structure is evident, i.e., they both utilize microtubule. However, our side-by-side comparison in [Figure 5](#f5-ajas-30-6-781){ref-type="fig"} shows that anti-Egr3 antibody produces a distinct pattern of subcellular localization compared to live imaging and anti-Xpress immunofluorescence staining. Anti-Xpress antibody detecting Xpress tag on the fusion construct ([Figure 1B](#f1-ajas-30-6-781){ref-type="fig"}) produced a signal much closer to Egr3-DsRed2 live imaging ([Figure 5](#f5-ajas-30-6-781){ref-type="fig"}), although the pattern was more diffused than that of DsRed2 live imaging. While we vigorously validated the specificity of antibodies in our previous investigation \[[@b2-ajas-30-6-781]\], it is possible that this anti-Egr3 antibody might produce artefactual pattern of localization in oocytes. Antibodies are often the most common culprits of problems in biological experiments due to non-specific binding to other proteins \[[@b19-ajas-30-6-781]\]. Whether this particular anti-Egr3 antibody detects other target(s) or processed form of Egr3 protein is not clear and it requires further validation.
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![Diagrams depicting the structure of *Egr3* gene and constructs used in this study. (A) The mouse *Egr3* gene and the variant detected by RT-PCR. Coding regions are shown as gray shaded areas. Locations of forward (F) and reverse (R) primers are shown as arrows. The variant has another exon (exon 2) in the middle thus the PCR product is 53 bp longer. The predicted size of translated product is shorter because it uses a downstream start codon at 168. Gray box, translated region; while box, untranslated region; black line, intron. (B) Fusion constructs used in this study. Full-length and truncated (ΔEgr3 without the first 249 amino acids) were cloned into pRSET vector containing Xpress epitope at the N-terminus. At the C-terminus, DsRed2 fluorescence tag was cloned in frame for live imaging. The locations of epitopes for the anti-Xpress and anti-Egr3 antibodies are shown. *Egr3*, early growth response protein 3; RT-PCR, reverse transcription-polymerase chain reaction.](ajas-30-6-781f1){#f1-ajas-30-6-781}

![mRNA expression of the *Egr3* gene in mouse ovaries and testes from 1 to 4 week-old mice. (A) Mouse ovaries from 1 to 4 week-old mice were subjected to RT-PCR. RNA from 4 week-old mouse testis was used as a positive control (+), and RNA from 4 week-old ovary without reverse transcription (RT) was used as a negative control (−). Expression of a housekeeping gene, *Rpl7*, was also examined. (B) Mouse testes from 1 to 4 week-old mice were subjected to RT-PCR. RNA from 4 week-old mouse ovary was used as a positive control (+), and RNA from 4 week-old testis without RT was used as a negative control (−). \*, *Egr3*; \*\*, a longer variant (NM_001289925.1). *Egr3*, early growth response protein 3; RT-PCR, reverse transcription-polymerase chain reaction; *Rpl7*, ribosomal protein L7.](ajas-30-6-781f2){#f2-ajas-30-6-781}

![Microinjection of truncated Egr3 cRNA does not hinder oocyte maturation. Xpress-Egr3-DsRed2 or Xpress-ΔEgr3-DsRed2 cRNA (0.0034 μM) was microinjected into GV oocytes in the presence of 200 μM IBMX and oocytes were kept in M16 containing IBMX for 8 h. They were then washed and cultured in IBMX-free M16 medium for 20 h. Localization of microinjected constructs were monitored by confocal live imaging examining the expression of red fluorescent protein, DsRed2. During oocytes maturation, both Xpress-Egr3-DsRed2 or Xpress-ΔEgr3-DsRed2 proteins are localized in nuclei and chromosomes. Expression of Xpress-Egr3-DsRed2 protein is lower than that of Xpress-ΔEgr3-DsRed2, as translation efficiency of Xpress-Egr3-DsRed2 is lower due to its length (about 750 bp longer than Xpress-ΔEgr3-DsRed2). White arrows indicate chromosomes. PI, prophase I; PMI, prometaphase I; MI, metaphase I; MII, metaphase II; *Egr3*, early growth response protein 3; GV, germinal vesicle; IBMX, 3-isobutyl-1-methylxanthine.](ajas-30-6-781f3){#f3-ajas-30-6-781}

![Microinjection of *Egr3* siRNA does not hinder oocyte maturation. (A) Western blot analysis of Egr3 in 293T cell co-transfected with pcDNA3.1/myc-his-Egr3 (Egr3-Myc) and *Egr3* siRNA (siEgr3) or non-targeting siRNA (siCON). Empty plasmid served as a negative control (Control). These cells were subjected to western blot analysis with anti-Egr3 antibody. Fifty micrograms of cell lysates were run on 10% SDS-PAGE gels. (B) Microinjection of *Egr3* siRNA in GV oocytes does not interfere with meiotic maturation. Confocal live image of meiotic spindle after co-injection of 0.5 μg/μL β-tubulin-EGFP cRNA and 25 μM *Egr3* siRNA or non-targeting siRNA. After microinjection, the oocytes were incubated in M16 medium supplemented with 200 μM IBMX for 8 h, then they were washed and cultured in IBMX-free M16 medium for 6 h. Spindle forms normally in both groups. MI, metaphase I; *Egr3*, early growth response protein 3; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; GV, germinal vesicle; EGFP, enhanced green fluorescent protein; IBMX, 3-isobutyl-1-methylxanthine.](ajas-30-6-781f4){#f4-ajas-30-6-781}

![Various methods of validating Egr3 localization in mouse oocytes and potential artefacts. Confocal live imaging and immunofluorescence staining with anti-Xpress and anti-Egr3 antibodies were compared in MI oocytes injected with Xpress-ΔEgr3-DsRed2 cRNA. GV oocytes were microinjected with Xpress-ΔEgr3-DsRed2 cRNA under IBMX and incubated for 8 h in M16 medium supplemented with IBMX. For oocyte maturation, these oocytes were placed in IBMX-free M16 medium for 8 h. At MI stage, oocytes were either subjected to confocal live imaging or immunofluorescence staining with indicated antibodies. *Egr3*, early growth response protein 3; MI, metaphase I; GV, germinal vesicle; IBMX, 3-isobutyl-1-methylxanthine.](ajas-30-6-781f5){#f5-ajas-30-6-781}

###### 

Primers used for reverse transcription-polymerase chain reaction

  Gene name                        Sequence (5′-3′)                 Product size (bp)   GenBank accession no.
  -------------------------------- -------------------------------- ------------------- -----------------------
  *Egr3*                           F: CAA TCT GTA CCC CGA GGA GAT   204                 NM_018781.3
  R: GCG AAC TTT CCC AAG TAG GTC   Variant: 257                     NM_001289925.1      
  *Rpl7*                           F: TCA ATG GAG TAA GCC CAA AG    246                 NM_011291.5
  R: CAA GAG ACC GAG CAA TCA AG                                                         

F, forward; R, reverse.

###### 

Meiotic maturation rate of oocytes injected with Xpress-Egr3-DsRed2 or Xpress-ΔEgr3-DsRed2 cRNA[1)](#tfn3-ajas-30-6-781){ref-type="table-fn"}

  Group                 Total oocytes   Oocytes maturation rate (%)   
  --------------------- --------------- ----------------------------- ------------
  Xpress-Egr3-DsRed2    85              84 (98.82)                    51 (60.00)
  Xpress-ΔEgr3-DsRed2   78              74 (94.87)                    52 (66.66)
  Water injection       40              40 (100)                      29 (72.50)
  No injection          68              65 (95.59)                    54 (79.41)

GVBD, germinal vesicle breakdown; MII, metaphase II; IBMX, 3-isobutyl-1-methylxanthine.

Microinjection was performed in the presence of IBMX and oocytes were incubated in M16 medium containing 200 μM IBMX for 8 h. They were then cultured in IBMX-free M16 medium for 20 h. GVBD was monitored after 3 to 5 h of culture and polar body extrusion (MII) after 20 h from the beginning of IBMX-free culture.

###### 

Meiotic maturation rate of oocytes injected with *Egr3* siRNA or non-targeting siRNA[1)](#tfn5-ajas-30-6-781){ref-type="table-fn"}

  Group                 Total oocytes   Oocytes maturation rate (%)   
  --------------------- --------------- ----------------------------- -------------
  *Egr3* siRNA          167             164 (98.20)                   119 (71.26)
  Non-targeting siRNA   155             146 (94.19)                   116 (74.84)
  No injection          63              62 (98.41)                    45 (71.42)

GVBD, germinal vesicle breakdown; MII, metaphase II; IBMX, 3-isobutyl-1-methylxanthine.

Microinjection was performed in the presence of IBMX and oocytes were incubated in M16 medium containing 200 μM IBMX for 8 h. They were then cultured in IBMX-free M16 medium for 20 h. GVBD was monitored after 3 to 5 h of culture and polar body extrusion (MII) after 20 h from the beginning of IBMX-free culture.

[^1]: These authors contributed equally to this work.
